Alcon Nevanac approval
Alcon's Nevanac (nepafenac ophthalmic suspension 0.1%) clears FDA Aug. 19 after a priority review for treatment of pain and inflammation associated with cataract surgery. Nepafenac, a new molecular entity and the first ophthalmic non-steroidal anti-inflammatory prodrug, converts intraocularly to the NSAID amfenac. Nevanac is administered to the eye three times daily beginning one day prior to cataract surgery and continuing through two weeks post-surgery, labeling states...
You may also be interested in...
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
After reviewing real-world data, the US agency says the decontamination systems should only be used for compatible facemasks and should not be used to clean a mask more than four times.
Under an extensive COVID-19 plan and executive order signed on 21 January, the US president explained how he’ll beef up testing and manufacturing of medtech to fight the virus.